韩国喘研究小组就严重喘临床缓解的定义达成共识:修改后的德尔菲研究
Sun Hye Shin1,2, Joon Young Choi3, Junghee Yoon2
1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
韩国专家建立了严重喘缓解的共识定义,强调症状控制和稳定的肺功能. 该框架旨在标准化韩国临床实践和研究的缓解标准.
科学领域:
- 肺部病理学 肺部病理学
- 呼吸系统医学 呼吸系统医学
- 临床共识 临床共识
背景情况:
- 喘缓解是一个关键的治疗目标,但缺乏标准化的定义.
- 不一致的定义阻碍了临床实践和研究,特别是在韩国,生物使用量不断增加.
研究的目的:
- 在韩国专家中建立韩国专家对严重喘临床缓解的共识定义.
- 为严重喘缓解创造一个区域相关和务实的框架.
主要方法:
- 一个经过修改的Delphi调查,涉及28名来自韩国结核病和呼吸系统疾病学院 (KATRD) 的肺病学家.
- 这是一项三轮调查,涉及6个领域和27个项目,通过使用协议率和内容有效率来分析共识.
主要成果:
- 共识定义的临床缓解是没有恶化,没有全身皮质类固醇,持续的症状控制 (喘控制测试≥20超过12个月),和稳定的肺功能.
- 完全缓解包括2型炎症标志物的正常化 (血液中乙素 <300/μL,FeNO <25 ppb).
- 肺功能评估依赖于对绝对值的临床判断.
结论:
- 德尔菲共识为在韩国定义严重喘缓解提供了一个务实的框架.
- 这一框架可以指导临床实践,指导方针的制定,以及对喘缓解的未来研究.
更多相关视频
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
09:58A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
相关概念视频
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Asthma-IV: Nursing Management
First, in...
